Daily Stock Analysis, EXEL, Exelixis Inc, priceseries

Exelixis Inc. Daily Stock Analysis
Stock Information
Open
19.21
Close
19.41
High
19.50
Low
19.09
Previous Close
19.26
Daily Price Gain
0.15
YTD High
25.31
YTD High Date
Mar 18, 2019
YTD Low
18.56
YTD Low Date
Sep 10, 2019
YTD Price Change
-0.52
YTD Gain
-2.61%
52 Week High
25.31
52 Week High Date
Mar 18, 2019
52 Week Low
13.42
52 Week Low Date
Oct 29, 2018
52 Week Price Change
2.71
52 Week Gain
16.23%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 7. 2017
20.57
Feb 23. 2017
21.75
11 Trading Days
5.72%
Link
LONG
Jun 19. 2017
21.60
Jul 27. 2017
26.43
27 Trading Days
22.37%
Link
LONG
Dec 19. 2017
26.68
Jan 8. 2018
30.21
12 Trading Days
13.23%
Link
LONG
Nov 1. 2018
14.95
Nov 12. 2018
15.97
7 Trading Days
6.80%
Link
LONG
Nov 13. 2018
16.65
Dec 17. 2018
20.87
22 Trading Days
25.35%
Link
LONG
Jan 4. 2019
20.73
Jan 18. 2019
22.23
10 Trading Days
7.26%
Link
Company Information
Stock Symbol
EXEL
Exchange
NasdaqGS
Company URL
http://www.exelixis.com
Company Phone
6508377000
CEO
Michael M. Morrissey
Headquarters
California
Business Address
210 E. GRAND AVE, SOUTH SAN FRANCISCO, CA 94080
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0000939767
About

Exelixis, Inc. is a biopharmaceutical company, which engages in the developing and commercializing small molecule therapies for the treatment of cancer. Its brands include COMETRIQ and cobimetinib. The company focuses on their proprietary resources and development and commercialization of cabozantinib. Exelixis was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994 and is headquartered in South San Francisco, CA.

Description

Exelixis, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer. The company's products include CABOMETYX for the treatment of patients with advanced renal cell carcinoma, who have received prior anti-angiogenic therapy; and COMETRIQ for the treatment of patients with progressive, metastatic medullary thyroid carcinoma. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors, which has shown clinical anti-tumor activity in approximately 20 forms of cancer and is the subject of a broad clinical development program. It also offers COTELLIC (cobimetinib), a selective inhibitor of MEK, in combination with vemurafenib for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma in the United States; and in combination with vemurafenib in other territories, including the European Union, Switzerland, Canada, Australia, and Brazil. Exelixis, Inc. has collaboration and license agreements with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds and programs. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.